337 related articles for article (PubMed ID: 17174517)
21. Ovarian preservation in stage I low-grade endometrial stromal sarcomas.
Li AJ; Giuntoli RL; Drake R; Byun SY; Rojas F; Barbuto D; Klipfel N; Edmonds P; Miller DS; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1304-8. PubMed ID: 16319256
[TBL] [Abstract][Full Text] [Related]
22. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.
Abeler VM; Røyne O; Thoresen S; Danielsen HE; Nesland JM; Kristensen GB
Histopathology; 2009 Feb; 54(3):355-64. PubMed ID: 19236512
[TBL] [Abstract][Full Text] [Related]
23. Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment.
Beck TL; Singhal PK; Ehrenberg HM; Rose PG; Lele SB; Krivak TC; McBee WC
Gynecol Oncol; 2012 Apr; 125(1):141-4. PubMed ID: 22119993
[TBL] [Abstract][Full Text] [Related]
24. [Treatment and prognosis of low-grade malignant endometrial stromal sarcoma].
Ma SK; Zhang HT; Wu LY; Liu LY; Li B
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):74-8. PubMed ID: 17575701
[TBL] [Abstract][Full Text] [Related]
25. [Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy].
Coquard R; Romestaing P; Ardiet JM; Mornex F; Sentenac I; Gérard JP
Bull Cancer; 1997 Jun; 84(6):625-9. PubMed ID: 9295866
[TBL] [Abstract][Full Text] [Related]
26. Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments.
Chauveinc L; Deniaud E; Plancher C; Sastre X; Amsani F; de la Rochefordiere A; Rozemberg H; Clough KB
Gynecol Oncol; 1999 Feb; 72(2):232-7. PubMed ID: 10021306
[TBL] [Abstract][Full Text] [Related]
27. Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer.
Patel S; Portelance L; Gilbert L; Tan L; Stanimir G; Duclos M; Souhami L
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1438-45. PubMed ID: 17418961
[TBL] [Abstract][Full Text] [Related]
28. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
[TBL] [Abstract][Full Text] [Related]
29. Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study.
Marchetti C; Pisano C; Mangili G; Lorusso D; Panici PB; Silvestro G; Candiani M; Greggi S; Perniola G; Di Maio M; Pignata S
Oncology; 2011; 81(2):104-12. PubMed ID: 21986449
[TBL] [Abstract][Full Text] [Related]
30. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
31. Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages.
Tanz R; Mahfoud T; Bazine A; Aassab R; Benjaafar N; El Khalil El Gueddari B; Ichou M; Errihani H
Hematol Oncol Stem Cell Ther; 2012; 5(1):31-5. PubMed ID: 22446608
[TBL] [Abstract][Full Text] [Related]
32. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
[TBL] [Abstract][Full Text] [Related]
34. Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study.
Seagle BL; Shilpi A; Buchanan S; Goodman C; Shahabi S
Gynecol Oncol; 2017 Aug; 146(2):254-262. PubMed ID: 28596015
[TBL] [Abstract][Full Text] [Related]
35. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
36. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.
Ghaemmaghami F; Karimi-Zarchi M; Gilani MM; Mousavi A; Behtash N; Ghasemi M
Asian Pac J Cancer Prev; 2008; 9(3):421-6. PubMed ID: 18990014
[TBL] [Abstract][Full Text] [Related]
37. [Clinical experience with uterine sarcoma].
Melilli GA; Di Gesù G; Loizzi V; Di Gesù A; Carriero C; Corsano P; Ferreri R
Minerva Ginecol; 1998; 50(7-8):291-5. PubMed ID: 9808951
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas.
Sorbe B; Johansson B
Int J Oncol; 2008 May; 32(5):1111-7. PubMed ID: 18425339
[TBL] [Abstract][Full Text] [Related]
39. Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough?
Feng W; Hua K; Malpica A; Zhou X; Baak JP
Int J Gynecol Cancer; 2013 Mar; 23(3):488-93. PubMed ID: 23435438
[TBL] [Abstract][Full Text] [Related]
40. Cervical sarcomas: an analysis of incidence and outcome.
Wright JD; Rosenblum K; Huettner PC; Mutch DG; Rader JS; Powell MA; Gibb RK
Gynecol Oncol; 2005 Nov; 99(2):348-51. PubMed ID: 16051326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
